PHYSICAL FUNCTION CHANGES FOLLOWING 12 WEEKS OF ANDROGEN RECEPTOR SIGNALING INHIBITORS FOR ADVANCED PROSTATE CANCER

Authors

Mark Belio, University of North Carolina at Chapel HillFollow
Sarah Blount, University of North Carolina at Chapel HillFollow
Ayange S. Ayangeakaa, University of North Carolina at Chapel HillFollow
Lillian C. Niehaus, University of North Carolina at Chapel HillFollow
Kailyn E. Lowder, University of North Carolina at Chapel HillFollow
Lauren Bates-Fraser, University of North Carolina at Chapel HillFollow
Young E. Whang, University of North Carolina at Chapel HillFollow
Claudio L. Battaglini FACSM, University of North Carolina at Chapel HillFollow
Erik D. Hanson FACSM, University of North Carolina at Chapel HillFollow

Abstract

BACKGROUND: Cross-sectional studies indicate that men with metastatic prostate cancer (PC) using androgen receptor signaling inhibitors (ARSI) have lower physical function (PF). However, the rate of change in PF remains unclear. This observational pilot study aimed to longitudinally examine objectively measured PF in men with advanced PC initiating ARSI treatment and after 12 weeks of therapy. Additionally, changes in grip strength, muscular power, and balance were determined. METHODS: Men with advanced PC (n=6, 70±9 y, 30.1±3.5 kg/m2 BMI) initiating ARSI completed testing at baseline and 12 weeks later. The majority (66.7%) of men were diagnosed with castration-sensitive metastatic PC. The primary outcome was PF, assessed using short physical performance battery [SPPB], timed up and go [TUG], and 400m walk. Secondary outcomes included grip strength (handgrip dynamometry), power (GymAware sit-to-stand power test mean and peak power) and balance (Sensory Organization Test composite score; somatosensory, visual, and vestibular ratios). Mean differences (MD) were calculated as 12-week follow-up - baseline. RESULTS: From baseline to 12 weeks of ARSI, there was a 4% improvement in 400m walk that approached significance [MD: -13 s; 95% CI (-25, -1); p=0.082, d=0.88]. However, there were no differences in PF as assessed by SPPB [MD: 0.33 points; 95% CI (-0.49, 1.16); p=0.465, d=0.32] and TUG [MD: -0.6 s; 95% CI (-1.4, 0.2); p=0.186, d=0.62]. For the secondary outcomes, there was a 9% decline in peak power [MD: -70.5 W; 95% CI (-124, -17.2); p=0.049, d=1.06]. However, there were no declines in mean power [MD: -18.7 W; 95% CI (-50.7, 13.4); p=0.305, d=0.47], grip strength [MD: -1.7 kg; 95% CI (-3.6, 0.2); p=0.149, d=0.70], or balance (composite score [MD: 0.2 pt; 95% CI (-6.2, 6.6); p=0.961, d=0.02], somatosensory ratio [MD: 1.3 pt; 95% CI (-2.4, 5.0); p=0.512, d=0.29], visual ratio [MD: 7.5 pt; 95% CI (-2.5, 17.5); p=0.203, d=0.60], and vestibular ratio [MD: 5.7 pt; 95% CI (-6.8, 18.2); p=0.416, d=0.36]). CONCLUSIONS: Contrary to prior cross-sectional studies, these preliminary results suggest that 12 weeks of ARSI do not adversely affect objectively measured PF. However, peak muscular power demonstrated a decline of large effect, which warrants further investigation as muscular power is closely linked with PF. Longer follow up (i.e., 24 weeks) and larger sample sizes are required to confirm these initial findings.

Recommended Citation

Belio, Mark; Blount, Sarah; Ayangeakaa, Ayange S.; Niehaus, Lillian C.; Lowder, Kailyn E.; Bates-Fraser, Lauren; Whang, Young E.; Battaglini, Claudio L. FACSM; and Hanson, Erik D. FACSM (2024) "PHYSICAL FUNCTION CHANGES FOLLOWING 12 WEEKS OF ANDROGEN RECEPTOR SIGNALING INHIBITORS FOR ADVANCED PROSTATE CANCER," International Journal of Exercise Science: Conference Proceedings: Vol. 16: Iss. 3, Article 105.
Available at: https://digitalcommons.wku.edu/ijesab/vol16/iss3/105